Special Issue "Molecular Players in Diagnostics and Therapeutics of Malignant Pleural Mesothelioma"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (31 July 2021).
2. Biotech Research & Innovation Center, University of Copenhagen, Ole Maaløes Vej 5, DK-2200 Copenhagen N., Denmark
Interests: malignant pleural mesothelioma; molecular alterations; novel biomarkers; molecular subtypes; diagnosis; prognosticators and predictors
Interests: malignant pleural mesothelioma; molecular alterations; novel biomarkers; prognosticators and predictors; targeted therapy; immunotherapy
Malignant pleural mesothelioma (MPM) is a very aggressive cancer originating from the mesothelial cells lining the pleural cavity, usually associated with exposure to asbestos or asbestos-like fibers and characterized by challenging diagnostics, poor response to current standard therapies, and dismal prognosis. MPM is difficult to distinguish from reactive pleural conditions using conventional imaging- and histopathology-based methodologies. Moreover, MPM displays one of the lowest somatic mutation burdens among cancers and is mainly driven by inactivation of specific tumor suppressor genes, rather than activating oncogene-mutations. These features complicate the implementation of targeted and immunological therapies for this cancer.
However, recent seminal comprehensive studies have enlightened the role played in MPM by important genetic, epigenetic, and immunological alterations as well as by the interplay between genetic cancer susceptibility and environmental factors. This allows delineating novel molecular and clinical subtypes, as well as promising diagnostic and therapeutic strategies for MPM.
This Special Issue, “Molecular Players in Diagnostics and Therapeutics of Malignant Pleural Mesothelioma”, aims at collecting and welcomes original research articles, state-of-the-art review articles, and commentaries in this field.
Prof. Dr. Eric Santoni-Rugiu
Prof. Dr. Jens Benn Sørensen
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Malignant pleural mesothelioma
- Molecular alterations
- Novel biomarkers
- Molecular subtypes
- Genetic cancer susceptibility
- Prognosticators and predictors
- Targeted therapy